In context
In late 2025, the surgical robotics market was rapidly expanding beyond traditional hospital operating rooms into ambulatory surgery centers (ASCs), driven by a broader shift toward outpatient and minimally invasive procedures. Distalmotion's funding round underscored the growing investor confidence in robotic systems designed for flexibility and value across diverse care settings.
What was reported
Distalmotion announced the closing of its Series G financing round, raising $150 million. The round was led by Revival Healthcare Capital with participation from existing investors. The funds are earmarked to accelerate US commercial adoption of its Dexter soft tissue robotic surgery system and to support ongoing clinical and product development.
A key focus of the US expansion is the ASC market, one of the fastest-growing segments in surgical care. The company also named Chas McKhann as executive chairman, bringing over 25 years of MedTech experience, including prior CEO roles at Apollo Endosurgery and Silk Road Medical.
Dexter has been integrated into clinical practice across Europe and the US, with nearly 3,000 patients treated. Recent FDA clearance in gynecology and product enhancements are expected to further drive adoption.
Why it mattered
This investment highlighted the strategic importance of ASCs as a growth frontier for surgical robotics, potentially reshaping how robotic surgery is deployed beyond traditional hospitals. Distalmotion's emphasis on simplified operations and value could pressure incumbents to adapt their offerings for outpatient settings, influencing the broader trajectory of minimally invasive surgery automation.
“Dexter delivers all the benefits of robotic surgery – dexterity, precision, and ergonomics – while also offering flexibility, efficiency, and value.”
Source: Robotics & Automation News (roboticsandautomationnews.com) · Published 2025-12-05 · “Distalmotion raises $150 million to expand Dexter robotic surgery system”